ARCHIVES

Drugs and Targets: EU approves Imbruvica in MCL, CLL

This article is from The Cancer Letter archive.

Vol. 40 No. 40 | October 24, 2014

Download PDF Visit The Full Archive

Related Articles

Amgen Replaces “Bundling” Contract With Three Separate Contracts For Growth Factors.

September 5, 2008

Cell Behavior Changes Noted At Baltimore Symposium

January 8, 1982

Virus Program Scientific Activities Report Concluded

August 22, 1975

FDA Approves Velcade Injection In Mantle Cell Lymphoma

October 31, 2014

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

June 29, 2012

December issue of Business & Regulatory Report included (an additional 8 pages of industry news).

December 10, 2004